FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Go back to FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 79.85 +0.14 (0.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.71 | 52 Week High | $10.00 | |||
| Open | $80.03 | 52 Week Low | $3.22 | |||
| Day High | $82.31 | P/E | N/A | |||
| Day Low | $79.22 | EPS | $-0.46 | |||
| Volume | 947,268 | |||||
